CN103479576B - 一种包裹阿霉素的聚乙烯亚胺-聚乙二醇-肌酸共聚物胶束及其制备方法 - Google Patents
一种包裹阿霉素的聚乙烯亚胺-聚乙二醇-肌酸共聚物胶束及其制备方法 Download PDFInfo
- Publication number
- CN103479576B CN103479576B CN201310448512.XA CN201310448512A CN103479576B CN 103479576 B CN103479576 B CN 103479576B CN 201310448512 A CN201310448512 A CN 201310448512A CN 103479576 B CN103479576 B CN 103479576B
- Authority
- CN
- China
- Prior art keywords
- peg
- creatine
- cooh
- polyethylene glycol
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960003624 creatine Drugs 0.000 title claims abstract description 61
- 239000006046 creatine Substances 0.000 title claims abstract description 61
- 229920001577 copolymer Polymers 0.000 title claims abstract description 52
- 239000004698 Polyethylene Substances 0.000 title claims abstract description 32
- 229920000573 polyethylene Polymers 0.000 title claims abstract description 32
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 title claims abstract description 30
- 229930195573 Amycin Natural products 0.000 title claims abstract description 30
- 239000000693 micelle Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 16
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 88
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 74
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 31
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 29
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 22
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 27
- 238000003756 stirring Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 229920002873 Polyethylenimine Polymers 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 9
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 9
- 229940014800 succinic anhydride Drugs 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000000703 high-speed centrifugation Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- -1 Polyethylene Polymers 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003937 drug carrier Substances 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- XEUCQOBUZPQUMQ-UHFFFAOYSA-N Glycolone Chemical compound COC1=C(CC=C(C)C)C(=O)NC2=C1C=CC=C2OC XEUCQOBUZPQUMQ-UHFFFAOYSA-N 0.000 abstract 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 229920006317 cationic polymer Polymers 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920001601 polyetherimide Polymers 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000011553 magnetic fluid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Polyamides (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310448512.XA CN103479576B (zh) | 2013-09-27 | 2013-09-27 | 一种包裹阿霉素的聚乙烯亚胺-聚乙二醇-肌酸共聚物胶束及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310448512.XA CN103479576B (zh) | 2013-09-27 | 2013-09-27 | 一种包裹阿霉素的聚乙烯亚胺-聚乙二醇-肌酸共聚物胶束及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103479576A CN103479576A (zh) | 2014-01-01 |
CN103479576B true CN103479576B (zh) | 2015-10-28 |
Family
ID=49820405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310448512.XA Active CN103479576B (zh) | 2013-09-27 | 2013-09-27 | 一种包裹阿霉素的聚乙烯亚胺-聚乙二醇-肌酸共聚物胶束及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103479576B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103768037B (zh) * | 2014-01-11 | 2017-10-20 | 华南理工大学 | 以双亲性化合物为载体的具有抗肿瘤和降低心脏毒性作用的缓释药物纳米微球及其制备方法 |
CN104072766B (zh) * | 2014-07-09 | 2016-08-24 | 中国科学院长春应用化学研究所 | 一种用于负载药物和基因的载体、药物-基因载体系统及其制备方法 |
CN106750047B (zh) * | 2016-11-28 | 2020-01-21 | 北京化工大学 | 一种表面正电荷的pH响应性阿霉素纳米药物胶囊的制备方法 |
CN110507612A (zh) * | 2019-05-28 | 2019-11-29 | 济南大学 | 基于alfa-亚麻酸修饰的单甲氧基聚乙二醇-寡壳聚糖的两性霉素B胶束及其制备 |
CN110200909A (zh) * | 2019-05-29 | 2019-09-06 | 济南大学 | 基于alfa-亚麻酸修饰的单甲氧基聚乙二醇-聚乙烯亚胺的两性霉素B胶束及其制备 |
CN111171375B (zh) * | 2020-02-04 | 2022-02-25 | 华月圆 | 一种pe用抗菌抗静电添加剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101574527A (zh) * | 2007-12-12 | 2009-11-11 | 华东师范大学 | 一种肝靶向型智能纳米胶束前药系统及其制备 |
-
2013
- 2013-09-27 CN CN201310448512.XA patent/CN103479576B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101574527A (zh) * | 2007-12-12 | 2009-11-11 | 华东师范大学 | 一种肝靶向型智能纳米胶束前药系统及其制备 |
Non-Patent Citations (1)
Title |
---|
磷酸肌酸对阿霉素引起的大鼠心脏毒性的预防保护作用;赵力等;《现代肿瘤医学》;20110731;第19卷(第7期);第1271页摘要部分 * |
Also Published As
Publication number | Publication date |
---|---|
CN103479576A (zh) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103479576B (zh) | 一种包裹阿霉素的聚乙烯亚胺-聚乙二醇-肌酸共聚物胶束及其制备方法 | |
KR101444274B1 (ko) | 약제복합체용 블록 공중합체 및 의약조성물 | |
CN105727309B (zh) | 双敏感两亲性多糖-阿霉素偶联物及其药学组合物的制备和应用 | |
EP2289946A1 (en) | A polyglycol modified chitosan oligosaccharide fatty acid graft, preparation method thereof and use of the same | |
JP2003511349A (ja) | 薬剤担体としてのポリ(ジペプチド) | |
CN102688498B (zh) | 紫杉烷类药物-羧甲基壳聚糖两亲性大分子前药、胶束制剂和冻干胶束制剂,及其制备方法 | |
CN112076159B (zh) | 具有不对称膜结构的载药聚合物囊泡及制备方法与在制备治疗急性髓系白血病药物中的应用 | |
CN103656652B (zh) | 一种双敏感响应型聚合物纳米胶束及其制备方法和应用 | |
CN111973556B (zh) | 载小分子药聚合物囊泡及其制备方法与应用 | |
CN103611165A (zh) | 透明质酸-环糊精-金刚烷聚乙二醇载体及其制备方法和应用 | |
WO2003015827A1 (en) | Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof | |
CN111407741A (zh) | 一种具有氧化还原与pH双响应的抗癌药物载体及其制备方法和应用 | |
CN106166299B (zh) | 一种载有阿霉素的可视化微泡复合物及其制备方法 | |
CN104367556A (zh) | 一种能提供一氧化氮的透明质酸硝酸酯去氧胆酸聚合物胶束的制备方法及其应用 | |
CN112480289B (zh) | 一种共担载阿霉素和铂类药物的核壳结构型壳聚糖基纳米前药及其制备方法和应用 | |
CN106176602A (zh) | 一种靶向作用于胃癌组织的多西紫杉醇壳聚糖纳米胶束及制备方法和应用 | |
JP6358797B2 (ja) | 癌を処置するためのウミロリムスおよびその誘導体の使用 | |
KR101429668B1 (ko) | 양친성 저분자량 히알루론산 복합체를 포함하는 나노 입자 및 그의 제조 방법 | |
Xu et al. | The design and synthesis of redox-responsive oridonin polymeric prodrug micelle formulation for effective gastric cancer therapy | |
CN105879051A (zh) | 一种自组装的核壳结构纳米药物的制备及应用 | |
KR101332001B1 (ko) | 양친성 저분자량 히알루론산 복합체를 포함하는 나노 입자 및 그의 제조 방법 | |
KR101323102B1 (ko) | 글리콜키토산-담즙산 복합체에 항암제가 봉입된 나노입자 및 그 제조방법 | |
CN103919738B (zh) | 一种甲氨喋呤前药及其胶束制剂和制备方法 | |
CN102552930B (zh) | 一种具有细胞靶向作用的水溶性紫杉醇衍生物及其制备 | |
CN107982543B (zh) | 一种蛋白质-异硫氰酸酯类键合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zou Fen Inventor after: Wei Kun Inventor after: Wei Shiqi Inventor before: Wei Kun Inventor before: Wei Shiqi Inventor before: Zou Fen |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220209 Address after: 510098 room 3513, No. 372, Huanshi East Road, Yuexiu District, Guangzhou, Guangdong Patentee after: Guangzhou Zhikun Biotechnology Co.,Ltd. Address before: 511458 Guangzhou Institute of industry, Huagong University, No. 25, Huanshi Avenue South, Nansha District, Guangzhou, Guangdong Patentee before: SOUTH CHINA University OF TECHNOLOGY |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231213 Address after: Room 3513, No. 372, Huanshi East Road, Yuexiu District, Guangzhou, Guangdong, 510030 Patentee after: Guangzhou Zhiyuan Biotechnology Co.,Ltd. Address before: 510098 room 3513, No. 372, Huanshi East Road, Yuexiu District, Guangzhou, Guangdong Patentee before: Guangzhou Zhikun Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right |